Daridorexant in children and adolescents with insomnia disorder: study protocol for a multicentre randomised controlled trial

INTRODUCTION: Insomnia disorder imposes a significant burden on children and adolescents; however, treatment options are limited. This paper describes the first controlled study to investigate the efficacy and safety of daridorexant, a dual orexin receptor antagonist, in children and adolescents with or without comorbid neurodevelopmental disorders, allowing its evaluation in a broad paediatric population.

via https://pubmed.ncbi.nlm.nih.gov/41942161/?utm_source=Other&utm_medium=rss&utm_campaign=None&utm_content=1L37KAMf2b_g4WEK3LmdFuKZu9pO3cN7u4ZmO9PPCPeBLMIw1q&fc=None&ff=20260421010909&v=2.19.0.post6+133c1fe